Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.

about

Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.

Item

http://www.wikidata.org/entity/Q46460183

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Evaluation of universal versus ...... ion pharmacokinetic modelling.

@en

Evaluation of universal versus ...... ion pharmacokinetic modelling.

@nl

type

Item

label

Evaluation of universal versus ...... ion pharmacokinetic modelling.

@en

Evaluation of universal versus ...... ion pharmacokinetic modelling.

@nl

prefLabel

Evaluation of universal versus ...... ion pharmacokinetic modelling.

@en

Evaluation of universal versus ...... ion pharmacokinetic modelling.

@nl

P1476

Evaluation of universal versus ...... tion pharmacokinetic modelling

@en

P2093

Alessandro Schipani

http://www.w3.org/2001/XMLSchema#string

Andrew Owen

http://www.w3.org/2001/XMLSchema#string

Saye Khoo

http://www.w3.org/2001/XMLSchema#string

P2860

Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy.

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.

Factors associated with lack of viral suppression at delivery among highly active antiretroviral therapy-naive women with HIV: a cohort study

Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa.

P304

165-172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKX334

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Adeniyi Olagunju

Oluseye Bolaji

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29029267

http://www.w3.org/2001/XMLSchema#string